Top in endocrinology: Novel procedure preserves GLP-1 weight loss; preclinical diabetes
Click Here to Manage Email Alerts
The FDA granted breakthrough device designation to an endoscopic procedure that resurfaces the duodenum lining to help people maintain weight loss after discontinuing GLP-1 receptor agonist treatment, according to a press release.
The FDA based its decision on results of a pooled analysis of previous studies of the duodenal mucosal resurfacing intervention (Revita, Fractyl Health). Results showed that patients with type 2 diabetes had durable weight loss maintenance following the outpatient procedure.
Initial results from the REMAIN-1 trial, which is comparing the Revita intervention with a sham procedure, are expected later this year.
“We believe durable weight maintenance is the single largest unmet need in obesity today, and we believe Revita is one of the only investigational products that is being evaluated in a pivotal study to test its potential to provide sustained weight maintenance,” Harith Rajagopalan, MD, PhD, co-founder and CEO of Fractyl Health, said in the release.
It was the top story in endocrinology last week.
In another top story, Jonathan D. Leffert, MD, spoke with Anna Casu, MD, about the preclinical stages of type 1 diabetes and who should be selected for screening.
Read these and more top stories in endocrinology below:
Duodenal mucosal resurfacing granted FDA breakthrough label for weight loss maintenance
The FDA granted breakthrough device designation for an endoscopic procedure that resurfaces the duodenum lining to allow for weight maintenance after discontinuation of a GLP-1 receptor agonist, according to an industry press release. Read more.
Q&A: Screening for type 1 diabetes may help slow disease progression
In part one of a three-part video exclusive series, Jonathan D. Leffert, MD, talks with Anna Casu, MD, about the preclinical stages of type 1 diabetes and who should be screened for the disease. Read more.
Q&A: New guidance for monitoring presymptomatic type 1 diabetes
In part two of a three-part video exclusive series, Jonathan D. Leffert, MD, talks with Rifka C. Schulman-Rosenbaum, MD, FACE, FACP, about the steps providers should take when a patient screens positive for type 1 diabetes. Read more.
Q&A: Assess full glucose profile, set a plan for treating early-stage type 1 diabetes
In part three of a three-part video exclusive series, Jonathan D. Leffert, MD, talks with Kimber Simmons, MD, MS, about how providers should discuss treatments for people with early-stage type 1 diabetes. Read more.
GLP-1s not tied to higher risk for form of optic neuropathy that may cause blindness
Adults using a GLP-1 receptor agonist do not have increased risk for nonarteritic anterior ischemic optic neuropathy, according to data from a retrospective analysis published in Journal of Diabetes Science and Technology. Read more.